These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37123626)

  • 1. Differentiation of astrocytoma between grades II and III using a combination of methionine positron emission tomography and magnetic resonance spectroscopy.
    Yano H; Miwa K; Nakayama N; Maruyama T; Ohe N; Ikuta S; Ikegame Y; Yamada T; Takei H; Owashi E; Ohmura K; Yokoyama K; Kumagai M; Muragaki Y; Iwama T; Shinoda J
    World Neurosurg X; 2023 Jul; 19():100193. PubMed ID: 37123626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas.
    Yano H; Ikegame Y; Miwa K; Nakayama N; Maruyama T; Ikuta S; Yokoyama K; Muragaki Y; Iwama T; Shinoda J
    Cureus; 2022 Jul; 14(7):e27157. PubMed ID: 36017268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes.
    Bisdas S; Ritz R; Bender B; Braun C; Pfannenberg C; Reimold M; Naegele T; Ernemann U
    Invest Radiol; 2013 May; 48(5):295-301. PubMed ID: 23296081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
    Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F
    J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.
    Kebir S; Lazaridis L; Weber M; Deuschl C; Stoppek AK; Schmidt T; Mönninghoff C; Blau T; Keyvani K; Umutlu L; Pierscianek D; Forsting M; Stuschke M; Antoch G; Sure U; Kleinschnitz C; Scheffler B; Colletti PM; Rubello D; Herrmann K; Glas M
    Clin Nucl Med; 2019 Jun; 44(6):e375-e381. PubMed ID: 30985412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system.
    Takei H; Shinoda J; Ikuta S; Maruyama T; Muragaki Y; Kawasaki T; Ikegame Y; Okada M; Ito T; Asano Y; Yokoyama K; Nakayama N; Yano H; Iwama T
    J Neurosurg; 2019 Aug; 133(4):1010-1019. PubMed ID: 31419796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Isocitrate Dehydrogenase Status in Non-Contrast-Enhanced Adult-Type Astrocytic Tumors Using Diffusion Tensor Imaging and
    Yasuda S; Yano H; Ikegame Y; Ikuta S; Maruyama T; Kumagai M; Muragaki Y; Iwama T; Shinoda J; Izumo T
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
    Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
    Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Immunogenetic Properties of Glial Tumors with Advanced Magnetic Resonance Imaging Findings.
    Gezer B; Mutlukan A; Sahinoglu M; Karabagli PN; Koktekir E; Karabagli H
    Turk Neurosurg; 2020; 30(3):422-427. PubMed ID: 32091123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive Assessment of
    Xing Z; Yang X; She D; Lin Y; Zhang Y; Cao D
    AJNR Am J Neuroradiol; 2017 Jun; 38(6):1138-1144. PubMed ID: 28450436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors.
    Server A; Josefsen R; Kulle B; Maehlen J; Schellhorn T; Gadmar Ø; Kumar T; Haakonsen M; Langberg CW; Nakstad PH
    Acta Radiol; 2010 Apr; 51(3):316-25. PubMed ID: 20092374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative
    Unterrainer M; Fleischmann DF; Vettermann F; Ruf V; Kaiser L; Nelwan D; Lindner S; Brendel M; Wenter V; Stöcklein S; Herms J; Milenkovic VM; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1368-1380. PubMed ID: 31486876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association between Whole-Brain MR Spectroscopy and IDH Mutation Status in Gliomas.
    Goryawala M; Saraf-Lavi E; Nagornaya N; Heros D; Komotar R; Maudsley AA
    J Neuroimaging; 2020 Jan; 30(1):58-64. PubMed ID: 31868291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas.
    Kong Z; Zhang Y; Liu D; Liu P; Shi Y; Wang Y; Zhao D; Cheng X; Wang Y; Ma W
    Ann Nucl Med; 2021 Apr; 35(4):493-503. PubMed ID: 33532992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping.
    Motomura K; Chalise L; Ohka F; Aoki K; Tanahashi K; Hirano M; Nishikawa T; Yamaguchi J; Shimizu H; Wakabayashi T; Saito R
    J Neurooncol; 2021 Jun; 153(2):361-372. PubMed ID: 34009509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[
    Bauer EK; Stoffels G; Blau T; Reifenberger G; Felsberg J; Werner JM; Lohmann P; Rosen J; Ceccon G; Tscherpel C; Rapp M; Sabel M; Filss CP; Shah NJ; Neumaier B; Fink GR; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1486-1495. PubMed ID: 32034446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.
    Suzuki K; Kawai N; Ogawa T; Miyake K; Shinomiya A; Yamamoto Y; Nishiyama Y; Tamiya T
    EJNMMI Res; 2021 Jul; 11(1):67. PubMed ID: 34291337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.